Affiliation:
1. Department of Genetic and Bioengineering, Faculty of Engineering, Alanya Alaaddin Keykubat University 07425,
Alanya, Antalya, Turkey
2. Department of Biology, Faculty of Science, Akdeniz University 07058, Antalya, Turkey
Abstract
Background:
Studies have shown that epigallocatechin-3-gallate (EGCG), which is present in green tea at a higher rate than other components, has an additive or synergistic cytotoxic effect when applied with different anticancer drugs and reduces the side effects caused by anticancer drugs. It is known that the order of administration of drugs in combined applications also affects cytotoxicity. In this context, in our study, the most effective application sequence was determined by evaluating the cytotoxic responses of epirubicin-HCl and EGCG according to the different application order in A-549 cells (NSCLC).
Methods:
To demonstrate the apoptotic activity, we detected changes in mRNA ratios of Bax, a pro-apoptotic gene, and Bcl-2, an anti-apoptotic gene, (Bax/Bcl2), as well as changes in the activity of caspase 3/7 enzyme. To demonstrate the effect of oxidative stress generation, we investigated changes in glutathione peroxidase activity.
Results:
It was observed that the cell viability of A-549 cells exposed to different concentrations of epirubicin-HCl and EGCG for 48 h decreased depending on the concentration increase. According to the results of cell viability in cells to which epirubicin-HCl (<IC50) and EGCG (<IC50) were treated with together, and the combination index (CI) value calculations, the most effective combination concentrations were determined to be IC20 Epirubicin-HCl and IC10 EGCG. LDH activities were found higher in epirubicin-HCl + EGCG treatment than epirubicin-HCl alone treatment compared to control groups. Treatment of epirubicin-HCl with EGCG was found to be more effective in increasing glutathione peroxidase activity than epirubicin-HCl alone. Both of epirubicin-HCl alone and combination traetments caused increase in Bax/Bcl-2 ratio in A-549 cells.
Conclusion:
Combination therapy of epirubicin-HCl with EGCG may be a light in the future for lung cancer patients who are tried to be treated with conventional chemotherapy drugs but cannot achieve the desired success.
Funder
Alanya Alaaddin Keykubat University Scientific Research Projects Unit
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine